JAK2 V617F Mutation is uncommon in chronic myelomonocytic leukaemia
Open Access
- 31 August 2005
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 130 (6), 968
- https://doi.org/10.1111/j.1365-2141.2005.05719.x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromesBlood, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Aberrant methylation of the negative regulators RASSFIA, SHP‐1 and SOCS‐1 in myelodysplastic syndromes and acute myeloid leukaemiaBritish Journal of Haematology, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997Journal of Clinical Oncology, 1999